ProPharma’s consultants have many years of industry experience implementing Part 11 and Annex 11. They leverage this experience to provide your organization with the benefits of a Part 11 or Annex 11 Gap Assessment, including:
Time to proactively remediate any critical deficiencies before an audit, rather than having them discovered by a regulator or customer
Insight to focus audit preparation activities on only those areas that need attention.
Confidence in the success of the next audit or inspection of your systems.
ProPharma’s Part 11 and Annex 11 experts follow risk-based GxP principles to prioritize the processes and systems to assess. They know which areas auditors are most likely to target and apply the following approach to assessing your systems and software validation procedures.
Meet with you to discuss your industry, your products, and your markets to determine the exact section of Part 11 and Annex 11 with which you need to comply.
Discuss any specific areas of concern. For example, you might feel confident about your software quality policies, but are uncertain whether or not your validation documentation will withstand...
Tailor ProPharma’s standard 200+ question Part 11 and Annex 11 assessment checklist to place the focus on the areas that are most important to your organization.
Conduct the Assessment in a manner similar to a regulator or potential customer. We ask the same tough questions, inspect your evidence, and challenge your practices.
Provide a Part 11 and Annex 11 Assessment Report with ratings for each question. Areas of non-compliance will be categorized as either “critical”, “major”, or “minor” in alignment with a risk-based...
Deliver a Compliance Action Plan with a list of specific, prioritized activities to complete to achieve Part 11 and Annex 11 compliance.
Host follow-up meetings to ensure that you understand the Part 11 and Annex 11 assessment results and recommended remediation activities.
Part 11 and Annex 11 contain very specific functional requirements for regulated systems. ProPharma’s consultants work with your technical experts to determine the specific system configurations needed for compliance. When systems require customization, they review the designs to ensure that the end-result will be compliant from the first release.
Access essential training and resources for Part 11 and Annex 11 at Validation Center, ProPharma knowledge center and resource.
Attend free webinars, enroll in online and in-person classes in the US and Europe, and download valuable templates and standard operating procedures. Validation Center offers everything you need for Part 11, Annex 11, and other validation and compliance training and resources.
October 21, 2026
Recent FDA enforcement activity is changing how MLR teams assess promotional risk. Learn why organizations are moving from defensible claims to predictive, enforcement-informed risk assessment.
October 19, 2026
Unlock AI success by understanding your data. Learn the foundations of AI readiness and how to build trust in your data for reliable insights.
October 13, 2026
Learn how to build a successful global medical information program in veterinary medicine, navigating complexity and enhancing customer support across diverse markets.
July 8, 2026
ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.
June 18, 2026
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
January 27, 2026
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
-1.png?width=320&height=185&name=6%20-%20Medical%20Information%20%20(650%20x%20425%20px)-1.png)
.png?width=320&height=185&name=7%20-%20FSP%20Solutions%20%20(650%20x%20425%20px).png)
.png?width=320&height=185&name=_5%20-%20Pharmacovigilance%20Solutions%20(650%20x%20425%20px).png)